Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections

Ooms, F.; Wouters, J.; Oscari, O.; Happaerts, T.; Bouchard, Géraldine; Carrupt, Pierre-Alain; Testa, Bernard; Lambert, D. M.

doi:10.1021/jm020995r

Scientific article

English

Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections

ContributorsOoms, F.; Wouters, J.; Oscari, O.; Happaerts, T.; Bouchard, Géraldine; Carrupt, Pierre-Alain; Testa, Bernard; Lambert, D. M.

Published inJournal of medicinal chemistry, vol. 45, no. 21, p. 4799-4799

Publication date2002

Affiliation Not a UNIGE publication

Citation (ISO format)

OOMS, F. et al. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections. In: Journal of medicinal chemistry, 2002, vol. 45, n° 21, p. 4799–4799. doi: 10.1021/jm020995r

Article

Identifiers

PID : unige:10620
DOI : 10.1021/jm020995r

ISSN of the journal0022-2623

486views

0downloads

Creation08/06/2010 1:48:45 PM

First validation08/06/2010 1:48:45 PM

Update time03/14/2023 4:00:27 PM

Status update03/14/2023 4:00:26 PM

Last indexation02/12/2024 7:10:36 PM

Archive ouverte UNIGE

Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling : additions and corrections

Technical informations